B
Bacchus Bio innovation
A High-Dimensional Fusion of Advanced Biotechnology and Digital Platform
About Bacchus Bio innovation
Bacchus Bio innovation Co., Ltd., established in March 2020, is a biotechnology firm that originated as a startup from Kobe University. The company was founded by Akihiko Kondo, a professor at Kobe University, who envisioned the convergence of chemical engineering and biotechnology after observing advanced automated labs and university-led ventures abroad in the 1990s. This experience formed the basis for the company's focus on bio-foundry research, driven by a desire to apply scientific advancements for societal benefit. Based in Kobe's Port Island, Bacchus Bio innovation leverages intellectual property and expertise from the university's advanced research in synthetic biology.
The core of the company's operations is its 'Integrated BioFoundry', a platform that provides an end-to-end service from microbial strain development to production process optimization. This foundry utilizes a 'Design, Build, Test, Learn' (DBTL) cycle, integrating digital technology with biotechnology to efficiently create highly functional microorganisms, or 'smart cells'. These engineered microbes are designed to produce a variety of useful substances, offering a transition from fossil fuel-based manufacturing to bio-based production. The company serves a diverse client base across the chemical, food, and pharmaceutical industries, helping them develop sustainable materials and products. Revenue is generated through contract services for substance production, technology development support, and the eventual commercialization of its own proprietary products.
Bacchus Bio innovation's service portfolio is multifaceted. The primary offering is the development of custom microorganisms for clients in sectors such as manufacturing, food, and healthcare. For instance, they can engineer microbes to produce alternative proteins, biopesticides, or materials for pharmaceuticals and chemicals that are otherwise difficult to synthesize. A notable service launched in spring 2023 is an 'intestinal microbiome culture model'. This model uses an in-vitro system to replicate the human gut environment, allowing food and functional material manufacturers to evaluate their products' effects on gut flora, thereby reducing development time and costs. A significant milestone was achieved in March 2023 when a joint proposal for developing technology to synthesize polymers directly from CO2 using microorganisms was selected for a Green Innovation Fund project by NEDO, a Japanese governmental agency.
Source: Dealroom company dataAt a glance
- Founded
- 2020
- Headquarters
- Kobe, Japan
News
Open roles
Bacchus Bio innovation in the Kobe ecosystem
The Bacchus Bio innovation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Rohto Pharmaceutical- TOTaiyo Oil
Science and Technology Entrepreneurship
DEFTA Partners- AFAlliance Forum Foundation
Sojitz
Shimadzu
Jgc
Megmilk Snow Brand
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bacchus Bio innovation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bacchus Bio innovation on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.